Establishment of pentraxin3 as a t-PA adaptive marker reflecting the progression of cerebral infarction
Project/Area Number |
17H07300
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Medical pharmacy
|
Research Institution | Fukuoka University |
Principal Investigator |
|
Research Collaborator |
Mishima Kenichi
Egawa Takashi
Sano Kazunori
Nakamura Yoshihiko
Irie Keiichi
Yamashita Yuta
|
Project Period (FY) |
2017-08-25 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 脳梗塞 / PTX3 / t-PA / バイオマーカー / 脳神経疾患 |
Outline of Final Research Achievements |
In this study, we examined whether the vascular inflammatory substance pentraxin 3 (PTX3) is useful as a marker for predicting the progression of cerebral ischemia using cerebral ischemic model mice and human clinical samples. As a result, we found that the plasma PTX3 concentration increases with the passage of time from the onset of cerebral ischemia. The most effective therapeutic agent for cerebral ischemia, t-PA, depends on the degree of progression of cerebral ischemia. If the relationship between PTX3 and the progression of cerebral ischemia is clarified, it will be easy to judge the appropriateness or inappropriateness of t-PA therapy.
|
Academic Significance and Societal Importance of the Research Achievements |
脳梗塞患者に対して、血栓を溶かすことができるt-PAを投与できるかどうかは、その患者の予後を大きく左右する。そのため、t-PA適応患者を見分ける基準が策定されることは、脳梗塞の後遺症を回避するために重要である。本研究成果をもとに、PTX3濃度と脳梗塞の進行度の関係性が更に明らかとなれば、脳梗塞発症時刻がわからない患者においても、ある程度の発症時刻を予測することができ、t-PAの適応患者の拡大に繋がると考えられる。
|
Report
(3 results)
Research Products
(7 results)
-
[Journal Article] Long-term treatment with thrombomodulin improves functional outcomes after cerebral ischemia even if administration is delayed2019
Author(s)
Nakano T, Nakamura Y, Matsuyama K, Irie K, Yasumura M, Hirata Y, Yamasaki M, Misumi K, Yamashita Y, Myose T, Matsuo K, Sano K, Kamimura H, Ishikura H, Egawa T, Mishima K.
-
Journal Title
Thromb Haemost
Volume: 119
Pages: 467-478
DOI
Related Report
Peer Reviewed
-
[Journal Article] Goreisan prevents brain edema after cerebral ischemic stroke by inhibiting aquaporin 4 upregulation in mice2018
Author(s)
Nakano T, Nishigami C, Irie K, Shigemori Y, Sano K, Yamashita Y, Myose T, Tominaga K, Matsuo K, Nakamura Y, Ishikura H, Kamimura H, Egawa T, Mishima K.
-
Journal Title
J Stroke Cerebrovasc Dis
Volume: 27
Pages: 758-763
DOI
Related Report
Peer Reviewed
-
[Presentation] ヒト遺伝子組み換えトロンボモジュリンの慢性期連日投与が脳梗塞の機能的予後に与える影響2019
Author(s)
中野 貴文, 仲村 佳彦, 入江 圭一, 松山 清, 山﨑 元貴, 安村 真子, 山下 郁太, 明瀬 孝之, 石倉 宏恭, 三島 健一, 江川 孝
Organizer
日本薬学会第139年会
Related Report
-
[Presentation] 脳虚血モデルマウスに対するアンチトロンビンⅢ製剤の有用性2019
Author(s)
岡野 志のぶ, 中野 貴文, 仲村 佳彦, 入江 圭一, 山崎 元貴, 神崎 愛, 山下 郁太, 明瀬 孝之, 佐藤 朝光, 松尾 宏一, 佐野 和憲, 三島 健一
Organizer
日本薬学会第139年会
Related Report
-
[Presentation] Long-term treatment with recombinant human soluble thrombomodulin improves ischemic brain damage via regulating systemic HMGB1 levels in mice2018
Author(s)
Nakano T, Nakamura Y, Irie K, Yamashita Y, Myose T, Takase Y, Matsuo K, Kamimura H, Ishikura H, Sano K, Egawa T, Mishima K.
Organizer
Neuroscience 2018
Related Report
Int'l Joint Research
-
-
[Presentation] Effect of delayed treatment with ADAMTS13 on cerebral ischemic injury compared with tPA2018
Author(s)
Nakano T, Irie K, Yamashita Y, Myose T, Sano K, Nakamura Y, Satho T, Kai M, Tominaga K, Kamimura H, Mishima K, Egawa T
Organizer
Neuroscience 2017
Related Report
Int'l Joint Research